AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

AdAlta's renounceable rights issue has raised $1.1 million before costs from existing and new shareholders. 

Chair, Paul MacLeman, commented: “We are poised to capitalise on the work done over the past year to transform our Company. We are excited by the potential for near term transactions to complete this transformation and unlock value for shareholders and would like to thank existing and new shareholders for their support of our strategy through the Rights Issue, particularly in these uncertain times.”

Advance  a first CAR-T product licensing transaction for its “East to West” cellular immunotherapy strategy in its AdCella subsidiary;

Advance business development transactions for existing assets, AD-214 and WD-34; and

Evaluate other strategic options for the Company, and to the extent any funds remain, fund general working capital.

Rights Issue raises $1.1million

Summary